On August 11, Autolus Therapeutics (NASDAQ:AUTL) reported second-quarter results that finally showed the kind of growth investors had been waiting years to see. Net product revenue hit $45.7 million, up 119% from $20.9 million a year earlier and up from $26.2 million just one quarter prior. Management used the momentum to raise full-year 2026 guidance to $140 million to $150 million, up from a prior range of $120 million to $135 million. For a company whose stock has been defined by cash burn and clinical promises, a quarter like this changes the conversation.
A Launch Finally Hitting Stride
The engine behind the quarter is AUCATZYL, Autolus’s CD19-directed CAR T therapy for adult relapsed or refractory B-cell precursor ALL. Revenue more than doubled year over year as demand grew inside existing authorized treatment centers and new centers came online, with the UK market adding to the total in its second quarter of availability there. Gross margin jumped to 55% in the second quarter, a sharp turn from 6% in the first quarter and from negative margins throughout all of 2025, a shift Autolus attributes to lower manufacturing cost per batch and reduced inventory write-offs. The balance sheet got reinforced too.
On August 3, Autolus signed a five-year, interest-only credit facility with Perceptive Advisors for up to $250 million, with $75 million funded at close on July 30, another $25 million available at the company’s option, and $150 million more tied to future revenue milestones. That capital, combined with the improving sales trajectory, pushed Autolus’s projected cash runway out to the second quarter of 2028. The company also picked up the 2026 Prix Galien UK Award for Best Biotechnology Product in June, and its pipeline keeps expanding beyond ALL, with trials underway in pediatric leukemia, lupus nephritis, progressive multiple sclerosis, and light-chain amyloidosis.
Growth Still Costs Real Money
The improvement has not erased the losses. Autolus posted a net loss of $39.1 million for the quarter, narrower than the $47.9 million loss a year earlier but still a loss, bringing the six-month net loss to $110.7 million. Selling, general and administrative expenses climbed to $41.2 million from $30.3 million, reflecting both commercialization costs in the US and UK and termination-related expenses tied to the workforce reduction the company announced in April, which cut roughly 13% of staff and is now substantially complete. Cash, cash equivalents and marketable securities actually fell during the quarter, ending June 30 at $201.6 million versus $229.4 million at the end of March, a reminder that revenue growth has not yet turned into cash generation.
AUCATZYL also carries a boxed warning covering cytokine release syndrome and neurologic toxicities, which occurred in 75% and 64% of trial patients, respectively, alongside a risk of secondary T cell malignancies. And a meaningful chunk of the new financing, $150 million of the $250 million facility, only arrives if Autolus hits specific revenue targets, meaning the strongest part of the capital raise is not guaranteed.
What The Smart Money Sees
Hedge fund ownership in Autolus fell to 11 funds in the most recent quarter from 14 in the quarter before, a pullback even as the revenue numbers improved. Short interest sits at 5.26% of float, a level that suggests some organized skepticism without signaling a heavily crowded short trade. That combination points to a stock where institutional conviction has not yet caught up to the operational improvement investors just saw on paper.
Where This Leaves Investors
Autolus enters the second half of 2026 with a business that looks structurally different than it did a year ago: revenue nearly tripling, margins turning positive, and fresh capital extending the runway into 2028. But the losses have not disappeared, cash on hand shrank during the very quarter revenue surged, and a large piece of the new financing depends on hitting sales targets that have not yet been met. For the growth story to hold, gross margin improvement needs to keep outpacing rising commercial costs.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
